High Expression of DC-STAMP Gene Predicts Adverse Outcomes in AML

Area of Science:

• Hematologic Oncology
• Molecular Biology
• Cancer Genomics

Background:

• Acute myeloid leukemia (AML) is a complex blood cancer with varied genetic profiles and poor patient outcomes.
• Identifying prognostic molecular markers is crucial for improving AML patient management and survival.

Purpose of the Study:

• To investigate the role of DC-STAMP expression as a prognostic biomarker in acute myeloid leukemia.
• To explore the molecular pathways and immune cell interactions associated with DC-STAMP in AML.

Main Methods:

• Analysis of RNA sequencing and clinical data from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases.
• Univariate and multivariate survival analyses, nomogram model construction, Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene Set Enrichment Analysis (GSEA), and protein-protein interaction (PPI) network analysis.
• Correlation analysis of DC-STAMP expression with immune cell infiltration and immune checkpoint genes.

Main Results:

• DC-STAMP expression was significantly elevated in AML patients and associated with adverse clinical factors and mortality.
• High DC-STAMP expression independently predicted unfavorable overall survival (OS) in AML patients.
• DC-STAMP expression correlated with specific signaling pathways (mTORC1, TNF-α), hub genes (PPBP, PF4), immune cell infiltration, and immune checkpoint gene expression.

Conclusions:

• Elevated DC-STAMP expression is a significant independent predictor of poor prognosis in acute myeloid leukemia.
• DC-STAMP may play a role in AML pathogenesis and immune evasion, representing a potential therapeutic target.